Objective: Plasma soluble CD40 ligand (sCD40L) is increased during HIV-1 infection, but it is unknown whether it circulates in monomeric or multimeric forms, and whether the circulating forms have differential effects on myeloid dendritic cell function and adaptive regulation.
Introduction
Myeloid dendritic cells are antigen-presenting cells (APCs) that orchestrate immune responses, serving as critical links between innate and adaptive immunity. Dendritic cells are powerful stimulators of CD4 þ and CD8 þ T cells and are responsible for priming antigenspecific T-cell responses [1] . Dendritic cells sense pathogens through pattern recognition receptors, leading to activation of signaling pathways that result in the expression of costimulatory molecules and secretion of cytokines that regulate the adaptive immune responses [2] . During HIV-1 infection, there is evidence of dendritic cell dysregulation and exhaustion, potentially contributing to generalized immune activation and inadequate adaptive immune responsiveness, which are hallmarks of HIV pathogenesis [3] . The cause of dendritic cell dysregulation during chronic HIV infection is incompletely understood, but we have recently shown that soluble plasma factors, independent of HIV itself, are contributors [4, 5] . Improved understanding of the soluble plasma factors that lead to dendritic cell dysregulation could provide therapeutic targets to potentially decrease immune activation, inflammation, and improve adaptive immune responses during HIV infection.
CD40 ligand (CD40L), also known as CD154, is a type II membrane glycoprotein of the tumor necrosis factor (TNF) family that is expressed as a trimer on activated T cells, B cells, monocytes, macrophages, endothelial cells, and platelets [6] . Cell-associated CD40L binds to its receptor CD40 on the surface of APCs to induce activation and to enhance the expression of B7 molecules to promote T-cell expansion [6] . Cell-associated CD40L binding also induces proliferation and immunoglobulin class switching of B cells [7] . Upon activation in vitro, cells shed a soluble form of CD40L in the form of a truncated 18 kDa monomer [8] [9] [10] . According to cellular distribution studies, platelets contribute to the majority of circulating soluble CD40 ligand (sCD40L) in plasma [11] . Plasma sCD40L levels are increased in various inflammatory states, such as cancer [12] and HIV infection [13] [14] [15] , including HIV-associated neuroinflammation [16, 17] . A major cause of increased sCD40L levels during chronic HIV infection is generalized platelet activation. We and others have shown that platelets have an activated phenotype during HIV infection, with increased expression of CD62 P-selectin, and hyperreactive responses to exvivo stimulation with platelet activating agents [18] [19] [20] . It is currently unknown whether sCD40L circulates as multimeric or monomeric forms in plasma during HIV infection. This distinction is important because these forms have differential immunologic effects. Multimeric forms of sCD40L are immunostimulatory to APCs [6, 21] , whereas monomeric forms of sCD40L play an overall immunosuppressive role [12] [13] [14] . Monomeric forms of sCD40L stimulate monocytes to express a proinflammatory phenotype and render both monocytes and plasmacytoid dendritic cells refractory to stimulation with Toll-like receptor (TLR) ligand stimulation [12, 14, 22] . Monomeric sCD40L exposure also favors the development of myeloidderived suppressor cells and regulatory T cells (Treg), both of which are elevated during HIV infection [12, 13] .
In this study, we focused on the characterization of sCD40L forms that circulate in the plasma of HIVinfected individuals. Although it is well established that levels of sCD40L are elevated during HIV infection [13] [14] [15] , it is not understood which forms of sCD40L are circulating, nor their differential effects on dendritic cell function. We found that both monomeric and multimeric forms of sCD40L are circulating in plasma. We tested whether there were differences in the ability of monomeric forms as compared with multimeric forms to affect dendritic cell phenotype and function as it relates to T-cell responsiveness and differentiation. We found that monomeric forms are much less dendritic cell activating than multimeric forms, but both forms ultimately result in dendritic cell dysfunction and related T-cell suppression upon subsequent TLR stimulation. We further tested plasma samples from our previously published study and detail preliminary findings for the effectiveness of low-dose aspirin in decreasing sCD40L during antiretroviral therapy (ART) treated chronic HIV infection, highlighting the potential for further testing of antiplatelet agents as immune modulatory therapy in chronic HIV infection.
Methods

Study population
The HIV-infected patients enrolled in this cross-sectional study who donated plasma samples for immunoblot analysis of circulating sCD40L were recruited through New York University AIDS Clinical Trial Unit and the Center for AIDS Research as previously described where healthy donors served as controls [4] . The HIV-infected patients who participated in the aspirin study were recruited and characterized as previously described [18] . Informed consent was obtained from all study participants in accordance with the Declaration of Helsinki. The studies were conducted in accordance with policies of the New York University Langone Medical Center institutional review board, Bellevue Hospital Center, and the central office of the New York City Health and Hospital Corporation.
Immunoblot analysis
About 1 ml of plasma each from eight HIV-infected donors virologically suppressed on ART and eight healthy control donors, randomly selected from our previous study [4] were processed using the ProteoMiner protein enrichment largecapacity kit (Bio-Rad, Hercules, California, USA), according to the manufacturer specification, to yield 100 ml of plasma enriched for medium-abundance and low-abundance proteins. Enriched plasma samples and recombinant sCD40L monomeric protein and multimeric protein were separated by SDS-PAGE, transferred to polyvinylidine difluoride (PVDF) membranes, and probed with mouse anti-CD40L (R&D Systems, Minneapolis, Minnesota, USA), followed by horse antimouse horseradish peroxidase (HRP) -conjugated secondary antibody (Cell Signaling Technology, Danvers, Massachusetts, USA). The blots were visualized using HRP substrate (Pierce, Life Technologies, Grand Island, New York, USA) by chemiluminescent detection.
For indoleamine 2,3-dioxygenase (IDO) detection, a total of 2.0 Â 10 5 cells were lysed in M-PER lysis buffer (Pierce, Life Technologies). Lysates were separated by SDS-PAGE, transferred to PVDF membranes, probed with rabbit anti-IDO antibody (Cell Signaling Technology), followed by goat antirabbit HRP -conjugated secondary antibody (Cell Signaling Technology) and mouse anti-B Actin (Santa Cruz, Biotechnology, Dallas, Texas, USA), followed by horse antimouse HRP -conjugated secondary antibody (Cell Signaling Technology). The blots were visualized using HRP substrate (Pierce, Life Technologies) by chemiluminescent detection.
Dendritic cell preparation and stimulation
Peripheral blood mononuclear cells were purified from buffy coats from uninfected donors purchased from the New York Blood Center (Queens, New York, USA) and plated at 50 Â 10 6 cells/10 ml per dish in Roswell Park Memorial Institute (RPMI) with 5% pooled human serum (PHS). Cells were allowed to adhere for 1-2 h at 378C. Nonadherent cells were removed by washing with RPMI. The adherent monocyte-enriched fraction was supplemented with 100 UI/ml rhGM-CSF and 300 UI/ml rhIL-4 (R&D Systems) on days 0 and 2. On day 5 of culture, dendritic cell were harvested, washed, and resuspended in RPMI supplemented with 5% PHS, purity more than 95% [lineage (LIN) negative, CD11c positive]. Dendritic cell (10 6 /ml) were incubated for 24 h with either sCD40L monomer (2 mg/ml; Enzo Life Sciences, New York, USA, ALX-522-015-6010) or sCD40L multimer, which is prepared using manufacturer's instructions by mixing monomer with Enzo's cross-linking enhancer (ALX-804-034-C050) at a ratio of 10 : 1, or enhancer alone. To evaluate for nonspecific effects of anti-CD40 ligation, appropriate controls included incubation of dendritic cells in the presence of enhancer, which appeared to be devoid of any functional effect. In certain experiments, dendritic cells were stimulated with Poly-ICLC (Hiltonol, Oncovir, Inc., Washington, DC, USA) at 5 mg/ml on day 6 for 18-20 h. To assess dendritic cell phenotype following sCD40L stimulation, dendritic cells were stained with conjugated fluorescent antibodies to CD11c (BD Pharmingen, San Diego, California, USA) and CD86 (BD Pharmingen). Secretion of interleukin-12p70, TNFa, and interleukin-6 was measured in dendritic cell supernatants using the Human Inflammatory Cytokine Cytometric Bead Array (BD Pharmingen).
Quantitative reverse transcriptase PCR
RNA from sCD40L-exposed dendritic cell (both monomer and multimer) and control-dendritic cell (n ¼ 3 per group) was isolated using RNAeasy Mini Kit (Qiagen, Valencia, California, USA) and converted to cDNA using RT 2 Streand Kit (SABiosciences, Qiagen, Valencia, California, USA). Expression of 84 genes central to TLR-mediated signal transduction were analyzed using the Human TLR signaling Pathway RT 2 Profiler PCR Array (SABiosciences, Qiagen, Valencia, California, USA) per manufacturer's protocol (for complete list of genes, see http://www.sabioscien ces.com/rt_pcr_product/HTML/PAHS-018A.html). Reactions were conducted using a BioRad iCycler iQ5 RT-PCR detection system. All data and statistics were analyzed via software provided by the manufacturer (http://www.sabiosciences.com/pcrarraydataanalysis. php).
Naive CD4 R T-cell coculture T-cell proliferation and interferon (IFN) g secretion assays were performed following coculture of carboxyfluorescein succinimidyl ester (CFSE) labeled allogeneic naive CD4 þ T cells with sCD40L-exposed dendritic cells AEstimulated with Poly-ICLC as described above. Naive CD4 þ T cells were purified by magnetic cell sorting (EasySep Human Naive CD4 þ T cell Enrichment Kit, Stem Cell Technologies, Vancouver, California, USA) from uninfected donor peripheral blood mononuclear cells and stained with 10 mmol/l CFSE dye (CellTrace CFSE Proliferation Kit, Life Technologies, New York, USA) for 10 min before incubation with dendritic cells at a ratio of 1 : 20 (dendritic cell/T cell). After 5-6 days, CFSE dilution was analyzed by fluorescence-activated cell sorting (FACS) and culture supernatants were assayed for IFNg using the Human Th1/Th2/Th17 Cytokine Cytometric Bead Array (BD Pharmingen).
Regulatory T-cell phenotype was analyzed after coculturing allogeneic naive CD4 þ T cells with sCD40L-exposed dendritic cells at a ratio of 1 : 10 for 7 days. Cells were stained with CD4 (BD Biosciences, San Diego, California, USA), FoxP3 (eBioscience, San Diego, California, USA), and CD127 (Biolegend, San Diego, California, USA) according to the manufacturer's instructions.
T-cell anergy assay
Dendritic cells were incubated for 48 h with sCD40L forms, lipopolysaccharide (LPS) 100 ng/ml (Sigma-Aldrich, St Louis, Missouri, USA), LPS 100 ng/ml þ IFNg 200 U/ml (R&D systems), or media control. Dendritic cells were washed well and mixed with allogeneic naive CD4 þ T cells at a 1 : 10 ratio. After 6-7 days, the T cells were stained with CFSE and were mixed at various ratios with allogeneic dendritic cells (from the same donor as the original 48 h dendritic cell incubation) matured overnight with R848 10 mmol/l (3 M) (1 : 10, 1 : 30, and 1 : 300; dendritic cell : T cell). After 3 days, CFSE dilution was analyzed by FACS.
Inhibitors
1-Methyl-DL-tryptophan (1-MT) was purchased from
Sigma-Aldrich and used at a concentration of 200 mmol/l.
PD-1 and CTLA-4 staining
Dendritic cells were incubated for 48 h with sCD40L forms, LPS 100 ng/ml (Sigma-Aldrich), or media control, washed and then cocultured with allogeneic naive CD4 T cells for 7 days and stained for CTLA-4 PE Brilliant Violet 605 and PD-1 Brilliant Violet 605 (Biolegend) and analyzed by FACS.
Plasma soluble CD40 ligand quantification
Concentrations of sCD40L were determined in plasma by commercially available quantitative ELISA (Bender MedSystems BMS293; eBioscience, San Diego, California, USA) according to manufacturer's instructions.
Statistics
Statistical analysis was performed on at least three independent experiments. Analyses of variance was performed for an overall comparison among independent groups if at least three groups were present, and Student's t-tests were then used for specific pairwise comparisons. In all cases, P values less than 0.05 using two-sided tests were considered significant. Results are presented as mean AE SEM of multiple donors where indicated.
Results
T cells or platelets that are activated in vitro release sCD40L monomers [8] [9] . However, it has been reported that sCD40L monomers, dimers, and trimers may circulate in the plasma in vivo [23] . Although it has been observed that total sCD40L is increased in the plasma of HIV-infected patients as compared with healthy controls [13] [14] [15] , the circulating form(s) of sCD40L have not been assessed during HIV infection. The immune activating effects of multimeric sCD40L have been extensively studied [6] [7] [8] , but recent studies suggest an immunosuppressive effect of monomeric sCD40L [12, 24] . To address the question of whether the monomeric or multimeric form is the predominant form of sCD40L circulating in plasma of HIV-infected patients as compared with healthy controls, we enriched plasma from eight HIV-infected donors and eight healthy control donors for medium-abundance and low-abundance proteins, followed by immunoblot of plasma (e) Dendritic cells were incubated with either sCD40L monomer (MONO), CD40L multimer (MULTI) as compared with control dendritic cell (NEG) overnight and then were subsequently stimulated overnight with Poly-ICLC, and interleukin-12 production was measured in cell supernatants by cytokine bead array. Shown in (c), (d), and (e) are data for three donors with statistical analysis using two-tailed Student's t-tests. sCD40L, soluble CD40 ligand; TNF, tumor necrosis factor. Ã P value < 0.05 and was considered significant.
preparations for sCD40L. We observed that multiple forms of sCD40L, including monomers (18 kD) and multimers of various sizes (26-40 kD) circulate in the plasma of both HIV-infected patients and healthy controls with relative ratios that vary by donor ( Fig. 1a ). To better understand the implication of our finding in HIV infection, wherein overall levels of plasma sCD40L are heightened [13] [14] [15] , we next sought to determine whether there were differential immunological effects of sCD40L forms on healthy control dendritic cells in vitro, using sCD40L concentrations tested in previous reports [12, 24] . We observed that maturation of dendritic cells (purity >95% CD11c þ LIN neg , Fig. 1b ) as assessed by CD86 expression was much higher after stimulation with multimeric sCD40L as compared with monomeric sCD40L (Fig. 1c ). Along these lines, multimeric sCD40L stimulated dendritic cells to secrete more interleukin-6 and TNF-a than monomeric sCD40L (Fig. 1d) . Notably, neither forms of sCD40L resulted in secretion of appreciable amounts of interleukin-12p70 by dendritic cells (not shown).
To further explore differences in activation of dendritic cells by sCD40L monomer as compared with multimer, a quantitative-PCR array with 84 genes delineating innate immune activation pathways was performed. Across all genes fold changes, there was no significant difference observed between dendritic cells treated with monomer vs. control as compared with multimer vs. control (Supplemental Figure 1 , http://links.lww.com/QAD/ A698). However, there was upregulation of more proinflammatory genes by multimeric sCD40L vs. control (interleukin-2, IRAK2, LY86, MAP2K3, TAB1, MYD88, NFKBIL1, REL, P < 0.05) as compared with monomeric sCD40L vs. control (LY86 and MYD88, P < 0.05) ( Table 1) .
To determine whether these circulating forms of sCD40L during HIV infection may contribute to dendritic cell dysfunction, we evaluated the ability of sCD40L-exposed healthy donor dendritic cells to produce cytokines, in particular interleukin-12, upon subsequent stimulation with a TLR 3 ligand, Poly-ICLC; an established potent inducer of interleukin-12 secretion [4, [25] [26] [27] . Interleukin-12 is an important regulatory cytokine that plays a pivotal role in the differentiation of naive CD4 þ T cells toward the Th1 pathway to generate antiviral cytotoxic T cells and IFNg secretion [28] . Secretion of interleukin-12 by dendritic cells in the setting of HIV infection is impaired, and likely impacts the formation of effective immune responses during HIV infection [4, 5, [29] [30] [31] . The mechanism of this dysfunction is only partially delineated, with a strong contribution by nonviral soluble plasma factors [4, 5] . Exposure to both sCD40L monomer and sCD40L multimer resulted in diminished secretion of interleukin-12p70 secretion by dendritic cell upon Poly-ICLC stimulation as compared with control ( Fig. 1e ).
We next studied the effects of healthy donor dendritic cells that were differentially incubated with sCD40L forms on naive CD4 þ T-cell skewing and proliferation. As previously reported, dendritic cells activated with multimeric sCD40L induced strong proliferation and Th-1 skewing of CD4 T cells as measured by CFSE dilution and IFNg secretion ( Fig. 2a and b) [6] . In contrast, dendritic cells exposed to monomeric sCD40L stimulated T cells to proliferate minimally only in certain donors, with no effect on others. Overall, there was no difference in proliferation by dendritic cells exposed to monomeric sCD40L compared with unstimulated dendritic cells ( Fig. 2a and b ). Furthermore, monomeric sCD40Lexposed dendritic cells did not stimulate secretion of IFNg by naive CD4 þ T cells ( Fig. 2a and b) . When sCD40L-stimulated dendritic cells were subsequently activated with Poly-ICLC and cocultured with allogeneic naive CD4 þ T cells, there was a trend for both sCD40L forms to suppress IFNg secretion (Fig. 2c ).
IDO, expressed by APCs such as macrophages and dendritic cells, plays a key role in the differentiation of immunosuppressive Treg by catabolizing tryptophan into kynurenine [32, 33] . IDO-mediated effects likely tip the balance of Th17/Treg, favoring microbial translocation during chronic HIV infection [34] . Previous studies have presented inconsistent data on the role of sCD40L in IDO expression in dendritic cells [35] [36] [37] [38] . Additionally, the monomeric vs. multimeric forms have never been directly compared. Because sCD40L circulates in both forms during HIV infection, we sought to investigate whether there are differential effects of sCD40L on IDO expression by dendritic cells. IDO expression as measured via immunoblot was increased by dendritic cells exposed to both monomeric and multimeric forms, as well as LPS, a known inducer of IDO in dendritic cells [37] . To next evaluate whether monomeric as compared with multimeric sCD40L-stimulated dendritic cells had differential effects on the ability of dendritic cells to induce Treg formation, allogeneic naive CD4 þ T cells were cocultured with dendritic cells exposed to either monomeric or multimeric forms of sCD40L. We observed that both monomeric and multimeric sCD40L-stimulated dendritic cells induced increased levels of Tregs, reflected by the increase in FOXP3þ cells, as did dendritic cells stimulated with LPS and LPS/IFNg, known inducers of Treg formation (Fig. 3) .
To further investigate the suppressive effects of sCD40Lexposed dendritic cells on T-cell function, anergy assays were performed. Coculture of naive CD4 T cells with both sCD40L monomer and multimer-exposed allogeneic dendritic cells resulted in T-cell anergy as evidenced by decreased proliferation upon subsequent coculture with TLR-matured allogeneic dendritic cells from the original dendritic cell donor. Induction of anergy by both forms of sCD40L was to a similar degree as LPS and LPS and IFNg, potent TLR agonists and dendritic cell activators (Fig. 4a ). We next tested whether IDO and Treg formation played a role in the induction of anergy by dendritic cells differentially activated by sCD40L forms. To test this, we added an inhibitor of IDO, 1-MT, to the dendritic cell-T-cell coculture experiments. There was no reversal of anergy by 1-MT, thus demonstrating that IDO and Treg do not play a major role in the induction of T-cell anergy by sCD40L activated dendritic cells (Fig. 4b, Supplemental Figure 2 , http://links.lww.com/QAD/A698).
Discussion
Dendritic cell dysregulation contributes to HIV pathogenesis and may blunt adaptive immune responses to various pathogens and vaccines in infected individuals [3] . The defect in cytokine secretion, in particular interleukin-12, that has been observed by dendritic cells in the setting of HIV infection is particularly relevant to the induction of Th1-type responses to facilitate the formation of strong cytotoxic T cells that are critical for killing of infected cells, including latently infected cells [39] . Here, we demonstrate that multiple circulating forms of sCD40L may contribute to this dendritic cell dysfunction during HIV infection.
It is well described that circulating levels of sCD40L are elevated overall during both treated and untreated HIV infection [13] [14] [15] , at least in part secondary to platelet activation [18] . Here, we demonstrate that circulating sCD40L is comprised of multiple forms including monomeric and multimeric, in both seronegative and antiretroviral-treated seropositive donors. Previous data delineating the circulating forms of sCD40L in vivo are scant [23] , and often it has been assumed that the circulating forms are monomeric [12] [13] [14] . Prior assessments of circulating forms of sCD40L have been limited by technical challenges in the detection of lowabundance small plasma proteins. Here, we utilize a protein enrichment kit to concentrate small plasma proteins (ProteoMiner) that enhanced our ability to detect these forms via immunoblot. Although plasma sCD40L monomeric forms appeared as discrete bands, we observed that multimeric forms varied in size. Although our immunoblot study was meant to be descriptive, further proteomic analysis could better define whether these multimeric forms are modified [40] . Consistent with prior studies [41, 42] , we reveal a primary immunostimulatory role of multimeric sCD40L on dendritic cell. In contrast, we found minimal stimulation of dendritic cells by monomeric sCD40L. However, despite these differential primary effects, we found that both forms induce a hyporesponsive or exhausted phenotype in the setting of subsequent TLR stimulation, with significant reduction in interleukin-12 secretion by dendritic cell that leads to a trend toward downstream Th1-skewing defects. This closely resembles the phenotype of dendritic cells upon exposure to plasma from HIV-infected individuals that has been previously attributed to nonviral plasma factors [4, 5] . Given the fact that these forms of sCD40L have differential effects on dendritic cells in terms of activation, it is likely that the mechanism of dendritic cell hyporesponsiveness to subsequent stimulation also differs. Following strong activation by multimeric sCD40L, it stands to reason that dendritic cells may be refractory to subsequent stimulation because of a certain level of exhaustion as has been observed with sequential TLR stimulation [3, 4, 26] . However, in regards to monomeric sCD40L, wherein minimal dendritic cell activation is observed, it is less clear how further responsiveness to TLR stimulation is inhibited. In accordance with our findings in dendritic cells, decreased cytokine secretion, including interleukin-12, has been observed by monocytes following exposure to monomeric sCD40L [12] . Future studies investigating the mechanisms underlying these effects are warranted to better define intracellular pathways that are regulated by monomeric sCD40L in dendritic cells and other cell types.
Additionally, we describe that exposure of dendritic cells to both monomeric and multimeric sCD40L leads to the induction of IDO expression, T regulatory cell formation, and T-cell anergy that further blunts adaptive cytotoxic T-cell responses. The findings related to increased IDO expression and Treg formation by sCD40L are consistent with previous studies demonstrating this link [12, 13] ; however, we found that blocking T regulatory cell formation using the IDO inhibitor 1-MT did not reverse T-cell unresponsiveness in these experiments. This suggests that sCD40L exposure of Fig. 4 . Dendritic cells exposed to both monomeric and multimeric soluble CD40 ligand induce anergy, which is not reversed by indoleamine 2,3-dioxygenase inhibition. (a) Dendritic cells were incubated with sCD40L monomer (MONO), CD40L multimer (MULTI), LPS, LPS and IFN-g (LPS g), or control (À) for 48 h, washed and then cocultured with allogeneic naive CD4 þ T cells at a ratio of 1 : 10. After 6-7 days, the T cells were stained with CFSE and were mixed at various ratios with allogeneic dendritic cells, from the original dendritic cell donor, matured overnight with R848 10 mmol/l (3 M) (1 : 10, 1 : 30, and 1 : 300; dendritic cell : T-cell ratio). After 3 days, CFSE dilution was analyzed by FACS. Data is shown for three donors with T-cell proliferation (CFSE dilution) normalized to untreated T cells (T cells alone) stimulated with R848 dendritic cells. (b) The same anergy experiment was performed in the absence (À) MT or presence (þ) MT of 1-MT a specific inhibitor of IDO activity. Data are shown for one donor, representative of four donor experiments. 1-MT, 1-Methyl-DL-tryptophan; CFSE, carboxyfluorescein succinimidyl ester; IDO, indoleamine 2,3-dioxygenase; IFN, interferon; sCD40L, soluble CD40 ligand. Ã P value < 0.05 and was considered significant. dendritic cells leads to T-cell anergy through additional mechanisms. The induction of T-cell anergy is a complex and often multifactorial process for which many pathways have been implicated including the absence of costimulation and the presence of inhibitory signals, including PD-1 and CTLA-4 engagement [43] . In studies using cells from individuals with cancer, sCD40L is found to result in increased upregulation of PD-1 on T cells compared with cells from control donors [12] . Indeed, we also found that naive CD4 þ T cells that were cocultured with sCD40Lactivated dendritic cells (both monomeric and multimeric forms) resulted in upregulation of PD-1 and CTLA-4 on T cells (Supplemental Figure 3 , http:// links.lww.com/QAD/A698).
We had previously published data from a study of 1 week of low-dose aspirin therapy in HIV-infected individuals receiving suppressive ART that revealed decreases in markers of immune activation and modulation of innate immune function [18] . Now, upon further analysis of plasma samples for total sCD40L from this study, we found that 1 week of low-dose aspirin therapy significantly decreased sCD40L (Supplementary Figure  4 , http://links.lww.com/QAD/A698). Therefore, by reducing platelet activation and resultant release of sCD40L, aspirin therapy may improve innate immune function and decrease immune activation during chronic infection. The reduction of sCD40L following 1 week of low-dose aspirin was modest (mean 2.66 vs. 2.41, P ¼ 0.04), but it remains possible that more prolonged or more potent antiplatelet therapy may have additive benefit in lowering these levels, resulting in further augmentation of innate and adaptive immune function. In order to address this question, a randomized, placebocontrolled clinical trial is currently underway to better evaluate the immunomodulatory role(s) of aspirin therapy during HIV infection (NCT02155985).
